A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

This publication has 21 references indexed in Scilit:

• Relatively Low HIV Infection Rates in Rural Uganda, but with High Potential for a Rise: A Cohort Study in Kayunga District, Uganda
  PLOS ONE, 2009
• Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
  The Journal of Infectious Diseases, 2006
• Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
  The Journal of Infectious Diseases, 2006
• Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge
  Journal of Virology, 2006
• Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys
  Science, 2006
• Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
  The Journal of Experimental Medicine, 2006
• Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag
  Journal of Virology, 2005
• Placebo‐Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIV‐1 Infection
  The Journal of Infectious Diseases, 2005
• Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector
  AIDS, 2004
• Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1
  New England Journal of Medicine, 2000